PharmiWeb.com - Global Pharma News & Resources
12-Jul-2021

Hemoglobinopathy Market To Expand with an ASTONISHING CAGR The Forecast to 2027

Hemoglobinopathy Market To Expand with an ASTONISHING CAGR The Forecast to 2027

Summary

The synthesis defect of alpha globin gives rise to alpha thalassemia and defect in beta globin give rise to beta thalassemia. The structural hemoglobin variants occur due to alteration of alpha and beta chains that causes defect in structure.
Editor: Nirav Gokani Last Updated: 12-Jul-2021

Hemoglobinopathy is a group of blood disorders inherited from the parents that involve an abnormality in the hemoglobin structure. The disorder consists of both thalassemia and sickle cell disease (SCD). Typical symptoms such as shortness of breath, enlarged spleen, severe pain, and growth problems in children are evident.

The global Hemoglobinopathy market is estimated to account for US$ 523.4 Mn in terms of value in 2019 and is expected to reach US$ 1,001.6 Mn by the end of 2027.

Request a sample copy of help grow your business @ 
https://www.coherentmarketinsights.com/insight/request-sample/2801

Increasing pervasiveness of sickle cell disease is expected to fuel the global Hemoglobinopathy market growth over the forecast period. For instance, the study, ‘Prevalence of sickle cell disease and sickle cell trait among children admitted to Al Fashir Teaching Hospital North Darfur State, Sudan’, published in October 2019, revealed a ubiquity of 59 for sickle cell disorder.

Moreover, initiatives by the government to manage and treat hemoglobinopathies are also expected to support the global Hemoglobinopathy market growth. For instance, the Ministry of Health and Family Welfare, Government of India, in August 2018, issued the latest draft policy for hemoglobinopathies in India.

Europe, in 2018, followed by North America, held a dominant position in global Hemoglobinopathy market, reckoning a share of 32.6% in terms of value.

Hemoglobinopathy’s epidemiological data is incomplete and several emerging economies are unaware of the precise burden of these disorders. Hence, recognizing the socio-economic burden related to these disorders is expected to provide rewarding growth opportunities for players in the global Hemoglobinopathy market.

Moreover, education and awareness programs in the schools, colleges and community, relating to hemoglobinopathies are also expected to support the global Hemoglobinopathy market growth.

Regular Red Blood Cell (RBC) count segment in the global Hemoglobinopathy market was valued at US$ 161.4 Mn in 2019 and is expected to reach US$ 277.9 Mn by 2027 at a CAGR of 7.4% during the forecast period.

Companies Covered as part of this study include: Novartis AG, AstraZeneca, Bluebird Bio Inc., Bristol-Myers Squibb, Emmaus Medical, Inc., Acceleron Pharma, Inc., HemaQuest Pharmaceuticals Inc., Eli Lilly and Company, Celgene Corporation, and Acceleron Pharma, Inc.

Tailored Information as per niche requirement:

LIMITED TIME OFFER – Hurry Up!

Exclusive offer!!! Purchase the report at a discounted rate!!!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report : 
https://www.coherentmarketinsights.com/promo/buynow/2801

Detailed Segmentation

Global Hemoglobinopathy Market, By Test Type:

  • Routine Red Blood Cell (RBC) count
  • Genetic Testing
  • Hemoglobin by high performance liquid chromatography
  • Hemoglobin isoelectric focusing ( Hb IEF)
  • Hemoglobin electrophoresis (Hb ELP)
  • Hemoglobin solubility test

Global Hemoglobinopathy Market, By Indication:

  • Sickle Cell Disease
  • Beta Thalassemia
  • Alpha Thalassemia

Global Hemoglobinopathy Market, By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Clinics

Get PDF Brochure of help grow your business @ 
https://www.coherentmarketinsights.com/insight/request-pdf/2801 

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact us:

Mr. Shah

Senior Client Partner – Business Development

sales@coherentmarketinsights.com